Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Boehringer Ingelheim
Mallinckrodt
Medtronic
Express Scripts

Last Updated: November 30, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ALPHA-1-PROTEINASE INHIBITOR (HUMAN)

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for alpha-1-proteinase inhibitor (human)

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002333 ↗ A Study of Saquinavir and Zalcitabine, Used Alone and Together, in the Treatment of Advanced HIV Infection in Patients Who Stopped Taking or Who Cannot Take Zidovudine Completed Hoffmann-La Roche Phase 2 1969-12-31 To compare the safety, tolerance, and efficacy of saquinavir mesylate (Ro 31-8959) alone, zalcitabine (dideoxycytidine; ddC) alone, and both in combination, in patients discontinuing or unable to take zidovudine (AZT).
NCT00002334 ↗ A Study of Zidovudine (AZT) Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients With Little or No Previous Treatment Completed Hoffmann-La Roche Phase 3 1969-12-31 To compare, in zidovudine (AZT)-naive patients, the safety, tolerance, and efficacy of saquinavir mesylate (Ro 31-8959) alone versus AZT alone versus AZT in combination with Ro 31-8959, zalcitabine (ddC), or both. To compare various disease markers among the different regimens.
NCT00291720 ↗ Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure? Completed British Heart Foundation Phase 2 2005-04-01 Patients with kidney failure have a poor survival rate that is due to a much higher than average rate of heart and vascular disease. The reason that kidney failure causes heart disease is unknown but recent research suggests that a hormone called aldosterone, which is increased in patients with kidney disease may damage the heart and blood vessels. The investigators propose, using a randomized blinded trial, to find out whether drugs that inhibit the actions of aldosterone have beneficial effects on the cardiovascular system in patients with kidney failure
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for alpha-1-proteinase inhibitor (human)

Condition Name

Condition Name for alpha-1-proteinase inhibitor (human)
Intervention Trials
Alpha 1-Antitrypsin Deficiency 4
HIV Infections 3
COVID-19 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for alpha-1-proteinase inhibitor (human)
Intervention Trials
Alpha 1-Antitrypsin Deficiency 8
COVID-19 3
HIV Infections 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for alpha-1-proteinase inhibitor (human)

Trials by Country

Trials by Country for alpha-1-proteinase inhibitor (human)
Location Trials
United States 69
United Kingdom 4
Brazil 3
Canada 3
New Zealand 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for alpha-1-proteinase inhibitor (human)
Location Trials
Florida 6
Texas 6
Pennsylvania 5
New York 5
California 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for alpha-1-proteinase inhibitor (human)

Clinical Trial Phase

Clinical Trial Phase for alpha-1-proteinase inhibitor (human)
Clinical Trial Phase Trials
Phase 4 3
Phase 3 6
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for alpha-1-proteinase inhibitor (human)
Clinical Trial Phase Trials
Completed 11
Unknown status 4
Recruiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for alpha-1-proteinase inhibitor (human)

Sponsor Name

Sponsor Name for alpha-1-proteinase inhibitor (human)
Sponsor Trials
Kamada, Ltd. 3
Hoffmann-La Roche 2
University Hospital Birmingham 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for alpha-1-proteinase inhibitor (human)
Sponsor Trials
Other 23
Industry 17
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Boehringer Ingelheim
Dow
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.